Skip to main content
Equibles
EDIT logo

EDIT · Editas Medicine, Inc.

Track EDIT — free

Use EDIT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.23 +0.15 (+4.87%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Market Cap
$496.06M
Shares
153.58M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.23 Open$3.04 Day$3.04–3.23 52W close$1.67–4.15 Avg vol 30d2.2M Short int24.7M · 16.1% float · 14.6d Short vol51% Last earningsMay 5, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 5

Up next

Latest filing: 10-Q
filed Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$47.01M
Trailing 12 months
Net income (TTM)
−$73.95M
Trailing 12 months
Revenue growth YoY
+232.3%
Year over year
Operating margin
-161.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-24.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$155.91M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+41.3%
Year over year · more shares
Price change (1Y)
+28.2%
Trailing year
Short interest
16.1%
Latest settlement · 14.6 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.5 · calm Equity put/call 0.58
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +24%
above
Price vs 50-day avg +7%
above
RSI (14) 57
neutral
MACD trend Positive
52-week position 63%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +12%
trailing
6-month return +27%
trailing
YTD return +58%
this year
Relative strength +12%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+4% holders QoQ · +36 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.07% of float · ▲ +5.2% MoM · 14.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
219 holders — mid 3-yr range
Squeeze score 81
high risk · 0–100
Fundamentals
Strong
Revenue growth +133%
Y/Y
EPS growth +38%
Y/Y
Free cash flow $-165.8M
Balance sheet $88.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 84%
annualized · 1-yr
Max drawdown −60%
past year
ATR 6.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+24% Bullish
Price vs 50-day avg
+7% Bullish
RSI (14)
57 Neutral
MACD trend
Positive Bullish
52-week position
63% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+4% holders QoQ · +36 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.07% of float · ▲ +5.2% MoM · 14.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
219 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $3 · 63% Range high $4
vs 200-day avg +24% vs 50-day avg +7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
EDIT
Editas Medicine, Inc.
this stock
$496.06M +57.6% +132.6% — 16.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $141.42B +20.5% +46.2% 32.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.22B +7.2% +20.8% 20.5 2.3%
ARGX
Argenx SE
 $64.44B +22.9% — — 1.9%
CSLLY
Csl Ltd
 $60.55B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
219
% held
78.7%
Net QoQ
+68.4M sh
Top holder
TCG Crossover Management,…
Held Float
View
Held by Funds
Fund positions
151
View
Short & Settlement
Short Interest Rising
Shares short
24.7M
Days to cover
14.6d
Change
+1.2M sh
View
Short Volume
Short vol %
51%
As of
Sep 4, 2026
Short Total
View
Fails to Deliver
FTD shares
686
Value
$1.8K
As of
Jul 28, 2026
View
Off-Exchange
Off-exchange %
40.1%
Week of
Jul 27, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Daniel Goldman
Amount
$1.0K–$15.0K
Traded
Apr 10, 2023
View
Financials
Financials
Revenue (FY)
$40.5M
Net income (FY)
$-160.1M
EPS diluted
$-1.80
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 5, 2026
This year
16
View
Proposed Sales
Value
$16.7K
Shares
5.1K
Filed
Aug 31, 2026
View
Earnings & Events
Earnings Calls
Last call
Jun 4, 2026
View

Performance

5D 20D 120D MTD YTD
EDIT +2.2% +12.2% +27.2% +5.6% +57.6%
SPY +0.1% -0.4% +15.1% +0.4% +12.9%
vs SPY +2.1% +12.6% +12.1% +5.2% +44.6%
Key facts CIK 1650664 CUSIP 28106W103 13F (30d) 152 filings 152 filers Visit website Investor relations